GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2009

Sangretech Gives Bostwick Scientific Rights to Its Dendritic-Cell Technology

  • Sangretech Biomedical will provide Bostwick Scientific with exclusive rights to its dendritic-cell technology in certain territories. Sangretech’s technology will be used in the development and commercialization of VDC2008, Bostwick Scientific’s clinical-stage product candidate employing unloaded or virgin dendritic cells in combination with cryotherapy and other primary therapies to potentially treat prostate and other solid cancers.  


Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?